ImmunoGen Jumps on earnings beat

• 
  

Possible entry level $7.21 or on pullback to $6. 05
Target price $8.96 - $10
MAJOR DOWNTREND APPROACHING
ImmunoGen ( IMGN ) Q4 results:
Revenues: $44.9M (+235.1%).
Net Income: $4.8M (+111.5%); EPS: $0.03 (+110.7%); Quick Assets: $176.2M (-32.8%).
2020 guidance: Revenues: $60M - 65M.

Transition next generation anti-fol-ate receptor alpha ( ADC , IMGN151, to pre-clinical development in mid-2020.
Source seeking alpha
ImmunoGen , Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.